Regeneron launches VEGF Trap-Eye trial & gains $20 million

Article

Regeneron Pharmaceuticals has received a $20 million milestone payment from Bayer HealthCare following dosing of the first patient in a Phase III study of the VEGF Trap-Eye for the treatment of wet age-related macular degeneration (AMD).

Regeneron Pharmaceuticals has received a $20 million milestone payment from Bayer HealthCare following dosing of the first patient in a Phase III study of the VEGF Trap-Eye for the treatment of wet age-related macular degeneration (AMD).

The Phase III study (VIEW 1: VEGF Trap Investigation of Efficacy and safety in Wet age-related macular degeneration) will be a non-inferiority comparison of the VEGF Trap-Eye and ranibizumab (Lucentis; Novartis). The randomized, double-masked study is expected to enrol approximately 1,200 subjects at more than 200 centres across the USA and Canada.

The VEGF Trap-Eye is a fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related placental growth factor (PlGF).

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.